lack of recruitment

The main objective of this study is to compare the proportions of late enhancement in patients with Left ventricular (LV) dysfunction as Herceptin ® and in a control group consisting of patients who did not have LV dysfunction after 6 months under the same treatment.

Inclusion Criteria:

• Women over 18 years
• Free and informed consent signed
• Histologically confirmed adenocarcinoma of the breast, metastatic or non-metastatic
• LVEF> 50% angioscintigraphy before the start of treatment with Herceptin ®,
• Overexpression of HER2 in the invasive component of the primary tumor (3 + 2 + according to ICH or with confirmation of positivity by FISH or CISH)
• Patient receiving treatment with Herceptin ®,
• Inclusion in the control group: patients treated with Herceptin ® episode without LV dysfunction,
• For the inclusion in the Group LV dysfunction: the appearance of a decrease in LVEF during treatment with Herceptin ®, angioscintigraphy identified.

Exclusion Criteria:

• Heart disease or serious medical conditions do not allow to administer Herceptin ® (documented history of heart failure, angina requiring treatment, severe dyspnoea at rest or oxygen dependency),
• History of ischemic heart disease or myocarditis
• Known allergy to trastuzumab, murine proteins or any of the excipients
• Patients with an indication against the MRI (claustrophobia, ferromagnetic foreign body, pacemaker or implantable defibrillator, known allergy to gadolinium salts)
• Renal impairment (creatinine clearance <60 ml / min according to the MDRD formula)
• Arrhythmia atrial fibrillation,
• Contraindications to the administration of Dotarem ®,
• Patient unable to give informed consent,
• Adult Trust,
• Pregnant or lactating
• Patient unable to undergo a medical for geographical, social or psychological.